Literature DB >> 9207418

Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia.

S Schwartz1, D Milatovic, E Thiel.   

Abstract

Invasive aspergillosis is an increasing problem in patients with acute leukaemia, bone marrow transplantation, immunosuppression after solid organ transplantation, or acquired immunodeficiency syndrome. Despite available antifungal treatment, the mortality approaches 100% in patients with dissemination of the infection into the central nervous system (CNS). Using a novel triazole, voriconazole, we successfully treated an Aspergillus brain abscess in a patient with acute leukaemia. Drug levels above the minimal fungicidal concentration for Aspergillus species were detected in cerebrospinal fluid (CSF) specimens, and the treatment achieved an objective response.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9207418     DOI: 10.1046/j.1365-2141.1997.972911.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  22 in total

Review 1.  Voriconazole: in the treatment of invasive aspergillosis.

Authors:  Richard B R Muijsers; Karen L Goa; Lesley J Scott
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Histological examination of an eye with endogenous Aspergillus endophthalmitis treated with oral voriconazole: a case report.

Authors:  Shakhsanam E Aliyeva; Andrew J Ullmann; Ulrike B Kottler; Martine Frising; Oliver Schwenn
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-03-30       Impact factor: 3.117

Review 3.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

4.  Voriconazole: the newest triazole antifungal agent.

Authors:  Nickie D Greer
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-04

5.  What is the role of therapeutic drug monitoring in antifungal therapy?

Authors:  Jeannina A Smith
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

6.  Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma.

Authors:  S Perea; G J Pennick; A Modak; A W Fothergill; D A Sutton; D J Sheehan; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

7.  Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis.

Authors:  Michael A Thiel; Annelies S Zinkernagel; Jürgen Burhenne; Claude Kaufmann; Walter E Haefeli
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

8.  Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods.

Authors:  Erika J Ernst; Keiko Yodoi; Ellen E Roling; Michael E Klepser
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 9.  Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.

Authors:  Rajendra S Kadam; Johannes N Van Den Anker
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

10.  Visual disturbance comorbid with hallucination caused by voriconazole in the Japanese population.

Authors:  Osamu Imataki; Hiroaki Ohnishi; Akira Kitanaka; Yoshitsugu Kubota; Toshihiko Ishida; Terukazu Tanaka
Journal:  Int J Hematol       Date:  2008-06-24       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.